Predictors of weight loss during treatment with <i>d</i>‐fenfluramine

Toornvliet, Arnoud C.; Pijl, Hanno; Hopman, Erica; Westendorp, Rudi G.J.; Meinders, A. E.

doi:10.1046/j.1365-2796.1997.131151000.x

Cited by 7 publications

(9 citation statements)

References 14 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have typically been conducted in only 50 ± 100 patients followed for 3 ± 12 months. 1,10,13,14,16,19 Our study showed that only body weight, treatment group and, to a lesser extent, age predicted weight loss and weight maintenance outcome and that the power of the prediction was quite low as only 7 ± 8% of the variation in weight change could be accounted for by these predictors. Using BMI did essentially not increase the predictive power, probably due to the high correlation between body weight and BMI in this population of subjects.…”

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

Hansen¹,

Astrup²,

Toubro³

et al. 2001

Int J Obes

View full text Add to dashboard Cite

BACKGROUND:In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects. MATERIAL: A total of 605 obese patients (BMI: 30 ± 45 kgam 2 ) of both gender were included from eight European centers and treated for 24 months. The patients were treated for the initial 6 months by Sib (10 mgaday) and a low-fat low-energy, individualized diet (600 kcaladay de®cit). The 467 patients who achieved b 5% weight loss after 6 months were randomized 3 : 1 to Sib (10 mgaday) (SibaSib) and placebo (SibaPla) for weight maintenance over a further 18 months. MAIN OUTCOME AND ANALYSES: Pre-treatment individual characteristics were assessed as predictors of 6 months weight loss (kg) and 24 months weight maintenance using simple and multivariate correlation and regression analyses. RESULTS: In univariate analyses, the 6 month weight loss (n 505) was positively associated with pre-treatment body weight (r 0.27), height (r 0.18), fat-free mass (r 0.21) (all P`0.001), fat mass (r 0.13, P`0.03), and resting metabolic rate (r 0.13, P`0.003). However, no relation was found with age, gender, smoking status, age at onset of obesity, or number of previous slimming attempts. The same predictors were found for weight change to endpoint in the SibaSib group (n 350), while no predictors were identi®ed in the SibaPla (n 114). In the multivariate regression analysis only pre-treatment body weight predicted weight loss at 6 months (P`0.001). Weight change (kg) to 24 month was predicted by: 4.34 0.07Ãbody weight (kg) 7 4Ãtreatment (Sib 1, Pla 0) 7 0.06Ãage (y), (r 2 8%, P`0.001). CONCLUSION: Only pre-treatment body weight seems to be an important independent predictor of 6 months weight loss and 24 month weight maintenance in this study on diet and Sib. As only 8% of the variation in 24 months weight change could be explained by the predictors, the clinical value of this information is limited.

show abstract

Section: Discussionmentioning

confidence: 57%

“…2 In other studies, no statistically signi®cant correlation between weight loss and initial bodyweight was found. 1,13 This could, at least partly, be explained by the relatively small number of subjects included in the studies and the duration of the trials.…”

Section: Discussionmentioning

confidence: 99%

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

Hansen¹,

Astrup²,

Toubro³

et al. 2001

Int J Obes

View full text Add to dashboard Cite

show abstract

“…Conversely, a low brain 5-HT level is associated with enhanced appetite (Leibowitz et al, 1987) and impaired impulse control in rats (Bizot, Le Bihan, Puech, Hamon, & Thiebot, 1999) and in humans at risk for alcoholism (Crean, Richards, & de Wit, 2002; LeMarquand, Benkelfat, Pihl, Palmour, & Young, 1999). Among obese humans, many medications that enhance serotonergic function induce weight loss (Hanotin, Thomas, Jones, Leutenegger, & Drouin, 1998; Pijl et al, 1991; Strain, Strain, & Zumoff, 1985; Toornvliet, Pijl, Hopman, Westendorp, & Meinders, 1997; Wadden et al, 2005), and reduce caloric intake (McTavish & Heel, 1992; Pijl et al, 1991; Wurtman et al, 1981) (although it should be noted that some serotonergic agents with prominent anticholinergic and antihistaminic action cause weight gain) (Ruetsch, Viala, Bardou, Martin, & Vacheron, 2005). Whether 5-HT plays a role in inhibitory control of eating in overweight individuals, specifically, has not been well studied.…”

Section: Introductionmentioning

confidence: 99%

Acute tryptophan depletion and sweet food consumption by overweight adults

et al. 2009

View full text Add to dashboard Cite

Serotonergic involvement has been implicated in preferential consumption of treat foods. We tested the effect of acute tryptophan depletion (ATD) on food consumption by overweight and lean adults with and without a history of recurrent major depressive disorder (MDD). ATD and taste-matched placebo challenges were administered double-blind in counter-balanced order. Participants were classified as lean (n = 36) or overweight (n=19) on the basis of body mass index (BMI). Total calorie, carbohydrate, protein, and sweet food consumption were assessed via a test meal 8-hours following ATD. Four food items of comparable palatability were offered as a part of the test: two sweet (one carbohydrate-rich, and one protein-rich) and two non-sweet (one carbohydrate-rich, and one proteinrich). As compared to the placebo challenge, ATD significantly increased sweet calorie intake among overweight participants and increased their propensity to consume sweet food first before any other type of food. Lean participants' sweet calorie intake and food preference were unaffected by ATD. Findings suggest serotonergic involvement in the sweet food consumption by overweight individuals.

show abstract

“…Accurate or sensitive predictors would be useful in selecting an appropriate treatment regimen for individual obese patients. Earlier studies suggest that a positive family history [1], repeated weight loss in the past and extreme body dissatisfaction were important factors in predicting weight loss [2]. Higher pretreatment body weight [3], resting metabolic rate (RMR), fat‐cell hyperplasia and upper body‐fat distribution [4] were associated with greater weight losses.…”

Section: Introductionmentioning

confidence: 99%

Predictors of programme adherence and weight loss in women in an obesity programme using meal replacements

Packianathan

Sheikh

Boniface

et al. 2004

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Objective: To explore predictors of programme adherence and weight loss in patients participating in a weight management programme using meal replacements (MR).Design: 150 healthy obese women, age 48.5(sd=8.3) years; weight, 97.6(13.4) kg; BMI 36.5(3.7), participated in a longitudinal study with a 16-week acute weight loss phase (Phase 1) followed by one year of a trial of weight loss maintenance (Phase 2). Energy intake during Phase 1 totaled 900 kcal (3.7MJ) a day from a diet including two meal replacements (MR). Energy intake during Phase 2 consisted of either MR or a low fat diet with a calculated energy deficit of 600 kcal/day (2.5MJ).Methods: Weight, height and waist circumference were measured and body composition assessed by air plethysmography (Bodpod). Glucose and insulin were measured by standard immunoassays and insulin sensitivity assessed by Homeostatic Model Assessment (HOMA).Results: At the end of 16 weeks, 114 subjects (76%) completed Phase 1 and achieved a mean weight loss of 8.95(3.38) kg. Adherence to Phase 1 was predicted by weight loss over the first two weeks (p<0.001). Weight loss during Phase 1 was predicted by initial weight and initial systolic blood pressure. Adherence to Phase 2 was not predicted by physiological measures. Weight loss maintenance in Phase 2 (not gaining more than 3% of the weight at start of phase 2) was predicted by cholesterol and triglyceride measured at the start of Phase 2 but otherwise was not predicted by the physiological measures. Initial insulin sensitivity did not predict weight loss in either phase.Conclusion: Participants whose weight loss over the first two weeks falls in the bottom third may need additional intervention if they are to continue in this type of programme. A battery of physiological measures at entry to a MR weight loss and maintenance programme explains only a very small proportion of the variation in weight loss.

show abstract

Predictors of weight loss during treatment with d‐fenfluramine

Abstract: Abstract. Toornvliet AC,

Cited by 7 publications

References 14 publications

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

Acute tryptophan depletion and sweet food consumption by overweight adults

Predictors of programme adherence and weight loss in women in an obesity programme using meal replacements

Contact Info

Product

Resources

About